1999

Unrecognized Hypertension in Diabetic Patients With Coronary Disease

Top

Tenenbaum A, Fisman EZ, Boyko V, et al. Unrecognized Hypertension in Diabetic Patients With Coronary Disease: Prevalence and Prognostic Significance. Eur Heart J. 1999;20:119, Abstr.730. Recent studies have shown a wide spreading of undiagnosed and accordingly untreated hypertension. However, scarce data are available regarding the prevalence and prognostic significance of the triple coexistence of undiagnosed hypertension, diabetes and ischemic heart disease.

Type 2 Diabetes & Acute Myocardial Infarction: Angiographic Findings & Results of Invasive Therapeutic Approach in Type 2 Diabetic Vs Nondiabetic Pts

Top

Waldecker B, Waas W, Haberbosch W, et al. Type 2 Diabetes and Acute Myocardial Infarction Angiographic Findings and Results of an Invasive Therapeutic Approach in Type 2 Diabetic Versus Nondiabetic Patients. Diabetes Care. 1999;22:1832-1838. Mortality in diabetic patients with acute myocardial infarction (MI) is high. The significance of the pretreatment coronary status in type 2 diabetic patients with acute MI, as well as the effect of mechanical revascularization using percutaneous transluminal coronary angioplasty (PTCA), has not been established.

Troglitazone: Antihyperglycemic Activity and Potential Role in the Treatment of Type 2 Diabetes(2)

Top

Scheen AJ, Lefebvre PJ. Troglitazone: Antihyperglycemic Activity and Potential Role in the Treatment of Type 2 Diabetes. Diabetes Care. 1999;22:1568-1577. Insulin resistance is a major component of type 2 diabetes; therefore, an insulin sensitizer agent like the thiazolidinedione compound troglitazone is considered a very promising drug. Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/d in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin.

Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant a-Lipoic Acid

Top

Ziegler D, Hanefeld M, Ruhnau KJ, et al.The ALADIN III Study Group. Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant a - Lipoic Acid: A 7-Month Multicenter Randomized Controlled Trial (ALADIN III Study). Diabetes Care. 1999;22:1296-1301. To evaluate the efficacy and safety of a-lipoic acid given intravenously, followed by oral treatment in type 2 diabetic patients with symptomatic polyneuropathy.

The Thiazolidinedione Rosiglitazone (BRL-49653) Lowers Blood Pressure and Protects Against Impairment of Endothelial Function in Zucker Fatty Rats

Top

Walker AB, Chattington PD, Buckingham RE, Williams G. The Thiazolidinedione Rosiglitazone (BRL-49653) Lowers Blood Pressure and Protects Against Impairment of Endothelial Function in Zucker Fatty Rats. Diabetes. 1999;48:1448-1453. Human obesity is associated with insulin resistance, hyperinsulinemia, and a predisposition to hypertension and vascular disease, the origin of which may lie in impairment of endothelial function.

The Natural History of Macular Edema After Cataract Surgery in Diabetes

Top

Dowler JGF, Sehmi KS , Hykin PG, Hamilton AMP. The Natural History of Macular Edema After Cataract Surgery in Diabetes. Ophthalmology. 1999;106:663-668. To determine the natural history of macular edema after cataract surgery in diabetes to provide a rational basis for laser therapy.

The Gly 972 Arg Amino Acid Polymorphism in IRS-1 Impairs Insulin Secretion in Pancreatic β Cells

Top

Porzio O, Federici M, Hribal ML, et al. The Gly972->Arg Amino Acid Polymorphism in IRS-1 Impairs Insulin Secretion in Pancreatic  Beta-Cells. J Clin Invest. 1999;104:357-364. Recent studies have identified several polymorphisms in the human insulin receptor substrate-1 (IRS-1) gene. The most prevalent IRS-1 variant, a GlyArg change at the codon 972, has been reported to be increased in prevalence among patients with type 2 diabetes.

The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals With Type 2 Diabetes

Top

Lim SC, A. Caballero E, Arora S, et al. The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals With Type 2 Diabetes. J Clin Endocrinol Metab. 1999;84:4159-4164. Estrogens protect healthy women from cardiovascular disease. However, epidemiological data suggest that women with diabetes are denied the cardioprotection associated with estrogens. Whether or not hormonal replacement therapy (HRT) confers cardiovascular benefits in postmenopausal women with diabetes is not known.

Serum Levels of Advanced Glycation End Products Are Increased in Patients With Type 2 Diabetes and Coronary Heart Disease

Top

Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF.  Serum Levels of Advanced Glycation End Products Are Increased in Patients With Type 2 Diabetes and Coronary Heart Disease. Diabetes Care. 1999;22:1543-1548. To investigate whether serum levels of advanced glycation end products (AGEs) and the glycoxidation product N-(carboxymethyl)lysine (CML) are increased in patients with type 2 diabetes compared with nondiabetic control subjects and whether levels of AGEs and/or CML differ in patients with type 2 diabetes with or without coronary heart disease (CHD).

Role of the Human Kidney in Glucose Counterregulation

Top

Meyer C, Dostou JM, Gerich JE. Role of the Human Kidney in Glucose Counterregulation. Diabetes. 1999;48:943-948. Animal experiments indicate that the kidney may play an important role in glucose counterregulation. Because the human kidney normally takes up and releases glucose, and since patients with end-stage renal disease are prone to hypoglycemia, we examined whether the kidney is also involved in human glucose counterregulation.

1 2 3 4 5 6 7 Next